A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Phase 1/2 Completed 52 enrolled Aldeyra Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis.

Timeline

Start: 2018-09-08
Primary completion: 2019-11-19
Completion: 2019-11-19

Publications

Results Cavanagh B, Gomes PJ, Starr CE, Nichols KK, Brady TC. Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial. Ophthalmol Ther. 2022 Aug;11(4):1449-1461. doi: 10.1007/s40123-022-00520-z. Epub 2022 May 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Reproxalap	Other / unclassified	0.25 %	Other
Subject	Reproxalap	Other / unclassified	0.5 %	Other

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Summary

Timeline

Publications

Drugs

Indications